ライフサイエンスコーパス: renal cell carcinoma

1 -treated cohorts (patients with melanoma and renal cell carcinoma).

2 (10%) of 31 (melanoma), and 14 (40%) of 35 (renal cell carcinoma).

3 ab versus sunitinib in first-line metastatic renal cell carcinoma.

4 t option for selected patients with advanced renal cell carcinoma.

5 , breast and colorectal cancers, melanoma or renal cell carcinoma.

6 gastrointestinal stromal tumour (wtGIST) and renal cell carcinoma.

7 with TSC include angiomyolipoma, cysts, and renal cell carcinoma.

8 ing lymphocytes in the context of clear cell renal cell carcinoma.

9 s at intermediate or poor risk with advanced renal cell carcinoma.

10 rome, known as hereditary leiomyomatosis and renal cell carcinoma.

11 , and 22.7 months (20.9-27.0) for those with renal cell carcinoma.

12 tandard of care for patients with metastatic renal cell carcinoma.

13 nephrectomy (CN) in patients with metastatic renal cell carcinoma.

14 or poor risk, previously untreated, advanced renal cell carcinoma.

15 ic target for the treatment of VHL-deficient renal cell carcinoma.

16 kers of survival in patients with metastatic renal cell carcinoma.

17 cy of treatments in patients with clear cell renal cell carcinoma.

18 nt of an aggressive form of type 2 papillary renal cell carcinoma.

19 y associated diseases including leukemia and renal cell carcinoma.

20 y of cabozantinib in advanced non-clear-cell renal cell carcinoma.

21 on correlates with poor clinical outcomes in renal cell carcinoma.

22 t to delay disease progression in clear cell renal cell carcinoma.

23 plus nivolumab for the treatment of advanced renal cell carcinoma.

24 be (chRCC, also known as kidney chromophobe) renal cell carcinoma.

25 he optimal approach in metastatic clear cell renal cell carcinoma.

26 or previously treated patients with advanced renal cell carcinoma.

27 or sunitinib in patients with non-clear cell renal cell carcinoma.

28 ant p.E318K also predisposes to melanoma and renal cell carcinoma.

29 d with sorafenib in patients with metastatic renal cell carcinoma.

30 rth-line therapy in patients with metastatic renal cell carcinoma.

31 using data from a recent study for treating renal cell carcinoma.

32 ease progression in patients with metastatic renal cell carcinoma.

33 ic urothelial carcinoma (mUC) and metastatic renal cell carcinoma.

34 correlated with YAP activation in clear cell renal cell carcinoma.

35 genes was linked to unfavorable prognosis in renal cell carcinoma.

36 itinib monotherapy in patients with advanced renal cell carcinoma.

37 axitinib as the standard of care of advanced renal cell carcinoma.

38 nib monotherapy in treatment-naive, advanced renal cell carcinoma.

39 een VHL and the m(6)A RNA demethylase FTO in renal cell carcinoma.

40 safety of cabozantinib across non-clear-cell renal cell carcinomas.

41 t to all targeted agents used to treat other renal cell carcinomas.

42 erent from the approaches used for classical renal cell carcinomas.

43 ption factor family translocation-associated renal cell carcinomas.

44 ons in the tumor suppressor TP53 are rare in renal cell carcinomas.

45 nign skin tumours, lung and kidney cysts and renal cell carcinoma(6,7).

46 In renal cell carcinoma, 8 samples reduced the list of clon

47 naive tumors, a papillary transitional cell renal cell carcinoma, a duodenal carcinoma, two metachro

48 nitiation of systemic therapy for metastatic renal-cell carcinoma; a decision that was made at the di

49 r prediction of local tumor recurrence after renal cell carcinoma ablation.

50 patients with previously untreated advanced renal cell carcinoma across all risk categories.

51 n of local tumor recurrence in patients with renal cell carcinoma after thermal ablation.

52 Pre-treatment determination of renal cell carcinoma aggressiveness may help guide clini

53 expressed in kidney, and is downregulated in renal cell carcinoma; also, its low expression correlate

54 s </= 10% of pheochromocytoma or early-onset renal cell carcinoma and </= 40% of CNS hemangioblastoma

55 viously published datasets of 100 clear-cell renal cell carcinoma and 99 non-small-cell lung cancer p

56 ically or cytologically confirmed metastatic renal cell carcinoma and at least two previous systemic

57 to uveal melanoma, mesothelioma, meningioma, renal cell carcinoma and basal cell carcinoma.

58 some 8q24.1 (encompassing MYC) in clear cell renal cell carcinoma and chromosome 11q13.3 (encompassin

59 ed by RECIST 1.1 in patients with clear cell renal cell carcinoma and how the progression events impa

60 ratumoral heterogeneity of a pair of primary renal cell carcinoma and its lung metastasis.

61 rtunity for previously treated patients with renal cell carcinoma and non-small-cell carcinoma.

62 versus sunitinib in patients with metastatic renal cell carcinoma and showed a favourable safety prof

63 r that proves effective in treating advanced renal-cell carcinoma and liver cancer.

64 s pheochromocytoma and paraganglioma (PPGL), renal cell carcinoma, and gastrointestinal stromal tumor

65 ed melanoma, reduced the need for surgery in renal cell carcinoma, and increased the number of patien

66 icates complement in the immune landscape of renal cell carcinoma, and notwithstanding cohort size an

67 g Wilms tumours, malignant rhabdoid tumours, renal cell carcinomas, and congenital mesoblastic nephro

68 umab + axitinib versus sunitinib in advanced renal cell carcinoma (aRCC).

69 Non-clear cell renal cell carcinomas are histologically and genetically

70 y of sunitinib in patients with locoregional renal-cell carcinoma at high risk for tumor recurrence a

71 Among patients with locoregional clear-cell renal-cell carcinoma at high risk for tumor recurrence a

72 ses have identified subtypes of conventional renal cell carcinoma broadly distributed into angiogenic

73 2) is active against metastatic melanoma and renal cell carcinoma, but treatment-associated toxicity

74 infiltrate in human lung adenocarcinomas and renal cell carcinomas can be reliably dissected with mas

75 A subset of patients with metastatic renal-cell carcinoma can safely undergo surveillance bef

76 eptor and a shift in the current standard of renal cell carcinoma care.

77 Clear cell renal cell carcinoma (CC-RCC) is the most lethal of all

78 lly quiet kidney tumor, clear cell papillary renal cell carcinoma (CCPAP).

79 care for patients with metastatic clear cell renal cell carcinoma (ccRCC) after failure of antiangiog

80 in mouse models of CAIX-positive clear cell renal cell carcinoma (ccRCC) and colorectal cancer.

81 ckpoint blockade (ICB) therapy in clear cell renal cell carcinoma (ccRCC) and other solid tumors.

82 In this study, we focused on clear cell renal cell carcinoma (ccRCC) and utilized RNA sequencing

83 tomic and epigenomic profiling of clear cell renal cell carcinoma (ccRCC) by The Cancer Genome Atlas

84 mask (VAM) in H&E micrographs of clear cell renal cell carcinoma (ccRCC) cases from The Cancer Genom

85 The adipocyte-like morphology of clear cell renal cell carcinoma (ccRCC) cells results from a grade-

86 esence of sarcomatoid features in clear cell renal cell carcinoma (ccRCC) confers a poor prognosis an

87 The genetic landscape of clear cell renal cell carcinoma (ccRCC) had been investigated exten

88 Clear cell renal cell carcinoma (ccRCC) has been previously classif

89 Although clear cell renal cell carcinoma (ccRCC) has been shown to result in

90 n of chromatin-modifying genes in clear cell renal cell carcinoma (ccRCC) has been uncovered through

91 on Hippel-Lindau (VHL)-associated clear cell renal cell carcinoma (ccRCC) has the potential to allow

92 ecent genomic studies of sporadic clear cell renal cell carcinoma (ccRCC) have uncovered novel driver

93 he molecular features that define clear cell renal cell carcinoma (ccRCC) initiation and progression

94 Clear-cell renal cell carcinoma (ccRCC) is a common aggressive urin

95 Clear cell renal cell carcinoma (ccRCC) is a gender-biased tumor.

96 Clear cell renal cell carcinoma (CCRCC) is an incurable malignancy

97 Clear cell renal cell carcinoma (ccRCC) is highly heterogeneous and

98 Clear cell renal cell carcinoma (ccRCC) is histologically defined b

99 Clear cell renal cell carcinoma (ccRCC) is the most common renal ca

100 Clear cell renal cell carcinoma (ccRCC) is the most common type of

101 mune profiling of samples from 73 clear cell renal cell carcinoma (ccRCC) patients and five healthy c

102 aled to be downregulated in human clear cell renal cell carcinoma (ccRCC) samples, which was also ver

103 -Lindau (VHL) are major causes of clear-cell renal cell carcinoma (ccRCC) that may originate from chr

104 This is particularly true of clear cell renal cell carcinoma (ccRCC) where, although key mutatio

105 an important prognostic factor of clear cell renal cell carcinoma (ccRCC), as well as a factor in gui

106 In clear cell renal cell carcinoma (ccRCC), AXL expression is associat

107 formed the management of advanced clear cell renal cell carcinoma (ccRCC), but the drivers and resist

108 In the most common form of RCC, clear cell renal cell carcinoma (ccRCC), inactivation of the von Hi

109 The most prevalent type, clear cell renal cell carcinoma (ccRCC), is characterized by geneti

110 been termed a tumor-suppressor in clear cell renal cell carcinoma (ccRCC), primarily based on functio

111 Some cancers, such as clear cell renal cell carcinoma (ccRCC), require exogenous glutamin

112 the signature initiating event in clear cell renal cell carcinoma (ccRCC), the most common form of ki

113 Clear-cell renal cell carcinoma (ccRCC), the most common subtype of

114 ted functional modules that drive clear cell renal cell carcinoma (ccRCC), we performed comprehensive

115 ressor and is highly expressed in clear cell renal cell carcinoma (ccRCC), where SLC2A3 expression is

116 pha) is a key oncogenic driver in clear cell renal cell carcinoma (ccRCC).

117 y, regulates lipid homeostasis in clear cell renal cell carcinoma (ccRCC).

118 BDs and is frequently mutated in clear cell renal cell carcinoma (ccRCC).

119 protein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).

120 iR-204 and miR-210 related to the clear cell Renal Cell Carcinoma (ccRCC).

121 used by VHL inactivation, such as clear-cell renal cell carcinoma (ccRCC).

122 le in improving the management of clear cell renal cell carcinoma (ccRCC).

123 implicated in the pathogenesis of clear cell renal cell carcinoma (ccRCC).

124 as indicative of poor survival in clear cell renal cell carcinoma (ccRCC).

125 lopment of adjuvant treatments in clear-cell renal cell carcinoma (ccRCC).

126 dulating metastasis of VHL-mutant clear cell renal cell carcinoma (ccRCC).

127 pes from The Cancer Genome Atlas: clear cell renal cell carcinoma (ccRCC, also known as kidney renal

128 More than 90% of clear cell renal cell carcinomas (ccRCC) exhibit inactivation of th

129 is inactivated in the majority of clear cell renal cell carcinomas (ccRCC), but genetic ablation of V

130 tion have been well described for clear cell renal cell carcinomas (ccRCC), but they are less studied

131 genetic event in the majority of clear cell renal cell carcinomas (ccRCC), leading to accumulation o

132 Most clear cell renal cell carcinomas (ccRCCs) have inactivation of the

133 is inactivated in the majority of clear cell renal cell carcinomas (ccRCCs), leading to inappropriate

134 is a critical tumor suppressor in clear cell renal cell carcinomas (ccRCCs).

135 Intriguingly, clear cell renal cell carcinoma cells (ccRCC) have a dysregulated l

136 27 induced apoptosis and cell death in 786-O renal cell carcinoma cells (EC(50) = 5 muM) and inhibite

137 ne treatment in a xenograft model using ACHN renal cell carcinoma cells did not differ from vehicle c

138 fically suppressed growth in patient-derived renal-cell carcinoma cells with endogenous PIK3Cbeta(D10

139 Chromophobe renal cell carcinoma (chRCC) accounts for approximately

140 Chromophobe renal cell carcinoma (chRCC) and renal oncocytoma are cl

141 Furthermore, type 2 papillary renal-cell carcinoma consisted of at least three subtype

142 However, clinically significant capture of renal cell carcinoma CTCs (RCC-CTCs) remains elusive due

143 te or poor risk per International Metastatic Renal Cell Carcinoma Database Consortium criteria.

144 were stratified by International Metastatic Renal Cell Carcinoma Database Consortium risk category a

145 d was stratified by International Metastatic Renal Cell Carcinoma Database Consortium risk status and

146 were categorised by International Metastatic Renal Cell Carcinoma Database Consortium risk status int

147 didate identified was the hepatocellular and renal cell carcinoma drug sorafenib.

148 characterization of the genome of clear cell renal cell carcinoma enabled identification of the roles

149 had been functionally disabled in the human renal cell carcinoma environment without unleashing unde

150 olizumab in patients with mUC and metastatic renal cell carcinoma, even in tumors that were classical

151 ansion of tumor-resident clones, we analyzed renal cell carcinomas from patients treated with stereot

152 circumstances and to cancer (paraganglioma, renal cell carcinoma, gastrointestinal stromal tumor) in

153 neous CT- and MRI-guided cryoablation of cT1 renal cell carcinoma had similar excellent intermediate-

154 Treatment for renal cell carcinoma has been revolutionised by inhibito

155 Renal cell carcinoma has long been understood to have a

156 For instance, ALK-rearranged renal cell carcinomas have shown responses to alectinib

157 INTERPRETATION: Renal cell carcinomas have the highest pan-cancer propor

158 Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is characterized by germlin

159 ancer syndrome hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a disease in which mutatio

160 ach to analyze hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a type of kidney cancer th

161 resent the case of endovascular treatment of renal cell carcinoma in patient with solitary kidney.

162 tween 1998 and 2010 for localised clear cell renal cell carcinoma in the USA).

163 tocrine/paracrine signaling in patients with renal cell carcinoma is associated with poor prognosis o

164 suppress ccRCC progression.The incidence of renal cell carcinoma is higher in males than in females

165 Identification of high-risk localised renal cell carcinoma is key for the selection of patient

166 cabozantinib in patients with non-clear-cell renal cell carcinoma is poorly characterised.

167 Renal-cell carcinoma is highly vascular, and proliferate

168 who undergo radical resection for localized renal cell carcinoma, is the preservation of kidney func

169 l carcinoma, which accounts for 15 to 20% of renal-cell carcinomas, is a heterogeneous disease that c

170 482 pathologically confirmed renal cell carcinoma lesions from 2008 to 2019 in a mult

171 is associated with other malignancies (e.g. renal cell carcinoma), little is known about the role of

172 presence of BAP1-associated cancers such as renal cell carcinoma, mesothelioma and meningioma, but n

173 rafenib efficacy in patients with metastatic renal cell carcinoma (mRCC) are not available.

174 ict the efficacy of everolimus in metastatic renal cell carcinoma (mRCC) patients are lacking.

175 is a standard initial therapy in metastatic renal cell carcinoma (mRCC), but chronic dosing requires

176 TOR (mTORi) approved for treating metastatic renal cell carcinoma (mRCC).

177 us a tyrosine kinase inhibitor in metastatic renal cell carcinoma (mRCC).

178 iogenic therapy is efficacious in metastatic renal cell carcinoma (mRCC).

179 standard second-line therapy for metastatic renal cell carcinoma (mRCC).

180 2%]), cutaneous melanoma (n = 38 [18%]), and renal cell carcinoma (n = 20 [9%]).

181 argeted therapies in advanced non-clear cell renal cell carcinoma (ncRCC) compared with clear cell re

182 many advances in the treatment of metastatic renal cell carcinoma of the clear cell type.

183 nib is approved for patients with metastatic renal cell carcinoma on the basis of studies done in cle

184 cer, 37 (33%) had melanoma, and 38 (34%) had renal cell carcinoma; one (<1%) patient had triple-negat

185 d tissues from patients and murine models of renal cell carcinoma, pancreatic ductal adenocarcinoma,

186 Methods: In a relevant renal cell carcinoma patient-derived xenograft model, we

187 e serum metabolites in advanced melanoma and renal cell carcinoma patients treated with nivolumab, an

188 ibly increased complications following CN in renal cell carcinoma patients, when TKI treatment is adm

189 the postoperative morbidity following CN in renal cell carcinoma patients.

190 CR ligands were expressed by patient-derived renal cell carcinomas (PD-RCC), and selective inactivati

191 tigate ITH and clonal evolution of papillary renal cell carcinoma (pRCC) and rarer kidney cancer subt

192 Purpose Patients with advanced papillary renal cell carcinoma (PRCC) have limited therapeutic opt

193 Papillary renal cell carcinoma (PRCC) is the most common type of R

194 he histomorphological subtyping of papillary renal cell carcinomas (pRCCs) has improved the predictio

195 cipients, for example, have a 7-fold risk of renal cell carcinoma (RCC) and 3-fold risk of urothelial

196 during tumour initiation and progression in renal cell carcinoma (RCC) and three oncometabolites - f

197 ined that CCR4 was highly expressed in human renal cell carcinoma (RCC) biopsies and observed abnorma

198 h an increased risk of developing clear cell renal cell carcinoma (RCC) but, paradoxically, obesity i

199 activation also stimulates proliferation of renal cell carcinoma (RCC) cell lines in vitro.

200 we identify PAX8 as a candidate oncogene in Renal Cell Carcinoma (RCC) cells.

201 Renal cell carcinoma (RCC) comprises a diverse group of

202 e somatic genetic and genomic alterations in renal cell carcinoma (RCC) encompassing the major RCC hi

203 sorafenib after surgical excision of primary renal cell carcinoma (RCC) found to be at intermediate o

204 For the past decade, advanced renal cell carcinoma (RCC) has been at the forefront of

205 The treatment landscape of metastatic renal cell carcinoma (RCC) has been revolutionized over

206 tment landscape for patients with metastatic renal cell carcinoma (RCC) has evolved dramatically.

207 The management pathways of advanced renal cell carcinoma (RCC) have considerably evolved in

208 ssification of patients across all stages of renal cell carcinoma (RCC) in plasma (area under the rec

209 Renal cell carcinoma (RCC) incidence is increasing world

210 Renal cell carcinoma (RCC) is a cancer with poor prognos

211 Cystic renal cell carcinoma (RCC) is almost certainly overdiagn

212 Renal cell carcinoma (RCC) is one of the most aggressive

213 Renal cell carcinoma (RCC) is one of the most lethal uro

214 Renal cell carcinoma (RCC) is polyresistant to chemo- an

215 ism underlying GM2-synthase de-repression in renal cell carcinoma (RCC) is poorly understood.

216 These findings show that angiogenesis in renal cell carcinoma (RCC) is regulated through AXL/S100

217 Renal cell carcinoma (RCC) is the most common type of ki

218 omics evaluation of 823 tumors from advanced renal cell carcinoma (RCC) patients identifies molecular

219 romo-1 (PBRM1) on TME and response to ICB in renal cell carcinoma (RCC) remains to be resolved.

220 Background Percutaneous ablation for cT1 renal cell carcinoma (RCC) remains underused, partially

221 Renal cell carcinoma (RCC) subtypes are characterized by

222 l carcinoma (ncRCC) compared with clear cell renal cell carcinoma (RCC) supports the study of combina

223 association studies have identified multiple renal cell carcinoma (RCC) susceptibility loci.

224 D), and otherwise PN; biopsy, with triage of renal cell carcinoma (RCC) to PN or ablation depending o

225 peutic response and resistance in metastatic renal cell carcinoma (RCC) treated with antiangiogenic t

226 Human renal cell carcinoma (RCC) tumors were stained for the N

227 etabolism, contributes to the progression of renal cell carcinoma (RCC) via a novel epitranscriptomic

228 the outcomes of microwave ablation (MWA) of renal cell carcinoma (RCC) with and without pyeloperfusi

229 d with bevacizumab in patients with advanced renal cell carcinoma (RCC) with variant histology or any

230 increasingly utilized treatment for stage I renal cell carcinoma (RCC), albeit without supportive le

231 of gastrointestinal stromal tumors (GISTs), renal cell carcinoma (RCC), and pancreatic cancer, has b

232 ty-related factors have been associated with renal cell carcinoma (RCC), but it is unclear which indi

233 In renal cell carcinoma (RCC), cells deficient in the von H

234 Eligible patients had metastatic renal cell carcinoma (RCC), endometrial cancer, squamous

235 Kidney cancer, or renal cell carcinoma (RCC), is a disease of increasing i

236 ation to acquired resistance to sunitinib in renal cell carcinoma (RCC), providing a pre-clinical rat

237 have been associated with increased risk of renal cell carcinoma (RCC), the most common form of kidn

238 s regions, obtained from three patients with renal cell carcinoma (RCC), were imaged.

239 amined the tumorogenic role of syntaxin 6 in renal cell carcinoma (RCC).

240 t cancer types but have yet to be studied in renal cell carcinoma (RCC).

241 ies (GWAS) have identified six risk loci for renal cell carcinoma (RCC).

242 l heterogeneity in MB, malignant glioma, and renal cell carcinoma (RCC).

243 alue of MPV in the prognostic evaluations of renal cell carcinoma (RCC).

244 and breast, but its role remains unclear in renal cell carcinoma (RCC).

245 therapy given as a first-line treatment for renal cell carcinoma (RCC).

246 ntrol mechanisms are only poorly analyzed in renal cell carcinoma (RCC).

247 lid tumors was followed by dose expansion in renal cell carcinoma (RCC).

248 itical role in the growth and progression of renal cell carcinoma (RCC).

249 receptors PD-1 and Tim-3 from patients with renal cell carcinoma (RCC).

250 nical trial of the combination in metastatic renal cell carcinoma (RCC).

251 rs (ICIs) are standard therapy in metastatic renal cell carcinoma (RCC).

252 ear cell carcinoma (KIRC) is the most common renal cell carcinoma (RCC).

253 cer epithelial cells, the cells of origin of renal cell carcinoma (RCC).

254 mg/kg in patients with melanoma (n = 16) and renal cell carcinoma (RCC; n = 15).

255 cluding normal kidney, renal oncocytoma, and renal cell carcinomas (RCC).

256 hereas EMT contributes to the development of renal cell carcinomas (RCC).

257 sorafenib vs placebo in resected unfavorable renal cell carcinoma [RCC]), the largest adjuvant trial

258 nitially effective against kidney cancer (or renal cell carcinoma, RCC); however, drug resistance fre

259 t can occur in most histological subtypes of renal cell carcinomas (RCCs) and carries a decidedly poo

260 for 100 consecutive biopsy-proved stage T1a renal cell carcinomas (RCCs) treated with percutaneous m

261 g staging system for prediction of localised renal cell carcinoma recurrence after surgery, which mig

262 SNPs) to improve the predictive accuracy for renal cell carcinoma recurrence and investigated whether

263 trates in lung adenocarcinoma and clear cell renal cell carcinoma, respectively.

264 h A498 primary site and ACHN metastatic site renal cell carcinoma (RRC) cell lines.

265 A subset of patients with metastatic renal-cell carcinoma show indolent growth of metastases.

266 Sarcomatoid clear-cell renal cell carcinomas (sRCC) are associated with dismal

267 er Genome Atlas breast cancer and clear cell renal cell carcinoma studies.

268 With the exception of renal cell carcinoma, studies assessing the association

269 ive ongoing studies targeting non-clear-cell renal cell carcinoma subtypes and specific molecular alt

270 TFE3 Xp11.2 translocation renal cell carcinoma (TFE3-RCC) generally progresses mor

271 s applied to a chicken embryo tumor model of renal cell carcinoma that was treated with two FDA-appro

272 dominant ganglioside isolated from malignant renal cell carcinoma tissues, is reported.

273 Guangdong, China) with localised clear cell renal cell carcinoma to examine 44 potential recurrence-

274 We observed renal cell carcinomas to have the highest proportion (0.

275 melanoma and a mouse model of translocation renal cell carcinoma (tRCC).

276 112 identified patients with non-clear-cell renal cell carcinoma treated at the participating centre

277 y of patients with metastatic non-clear-cell renal cell carcinoma treated with oral cabozantinib duri

278 71.9 years +/- 10.9) with 217 biopsy-proven renal cell carcinoma tumors treated with thermal ablatio

279 t non-invasively predicting Fuhrman grade of renal cell carcinoma using conventional MRI.

280 hrman I-II) from high-grade (Fuhrman III-IV) renal cell carcinoma using radiomics features extracted

281 common causes for radiologic progression of renal cell carcinoma were based on non-target disease an

282 ment-naive progressive metastatic clear cell renal cell carcinoma were enrolled between September 201

283 Glioma and renal cell carcinoma were prioritized because these tumo

284 Papillary renal-cell carcinoma, which accounts for 15 to 20% of re

285 of (99m)Tc-PHC-102 in SPECT in patients with renal cell carcinoma while also assessing the safety and

286 versus sunitinib in patients with metastatic renal cell carcinoma who express programmed death-ligand

287 hibitor everolimus in patients with advanced renal cell carcinoma who progressed after previous VEGFR

288 with histologically confirmed non-clear-cell renal cell carcinoma who received cabozantinib for metas

289 We identified 627 patients with Stage IV renal cell carcinoma who underwent CN from 2007-2010 uti

290 itrated axitinib in patients with metastatic renal cell carcinoma who were previously treated with ch

291 y, previously treated patients with advanced renal cell carcinoma who were randomly assigned to nivol

292 previously untreated, advanced or metastatic renal cell carcinoma with a clear-cell component were re

293 nced, or metastatic histologically confirmed renal cell carcinoma with a clear-cell component were re

294 18 years old) with treatment-naive, advanced renal cell carcinoma with clear cell histology were enro

295 ly confirmed locally recurrent or metastatic renal cell carcinoma with clear cell histology, a Karnof

296 chromophobe, or unclassified non-clear cell renal cell carcinoma with no history of previous systemi

297 ted MRI may be useful to identify clear cell renal cell carcinomas with higher growth rates.

298 ated intermediate-risk or poor-risk advanced renal cell carcinoma, with a manageable safety profile.

299 included patients with metastatic clear cell renal cell carcinoma, with at least one target lesion at

300 ucture, vascular perfusion, and hypoxia of a renal cell carcinoma xenograft model grown in the chorio